Aptivus

Aptivus is a brand name of tipranavir, approved by the FDA in the following formulation(s):

APTIVUS (tipranavir - capsule; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: June 22, 2005
  
  Strength(s): 250MG ^[RLD]

APTIVUS (tipranavir - solution; oral)

• 
  Manufacturer: BOEHRINGER INGELHEIM
  
  Approval date: June 23, 2008
  
  Strength(s): 100MG/ML ^[RLD]

Has a generic version of Aptivus been approved?

No. There is currently no therapeutically equivalent version of Aptivus available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aptivus. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Pyranone compounds useful to treat retroviral infections
  Patent 5,852,195
  Issued: December 22, 1998
  Inventor(s): Romines; Karen Rene & Bundy; Gordon L. & Schwartz; Theresa M. & Tommasi; Ruben A. & Strohbach; Joseph W. & Turner; Steven Ronald & Thaisrivongs; Suvit & Aristoff; Paul Adrian & Johnson; Paul D. & Skulnick; Harvey Irving & Skaletzky; Louis L. & Anderson; David John & Morris; Joel
  Assignee(s): Pharmacia & Upjohn Company
  The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl›b!pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV). ##STR1##
  
  Patent expiration dates:
  
  
  • June 22, 2019
    
    ✓ 
    Drug substance
  
  
  
  • December 22, 2019
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method for improving the pharmacokinetics of tipranavir
  Patent 6,147,095
  Issued: November 14, 2000
  Inventor(s): Ferry; James J. & Baldwin; John R. & Borin; Marie T.
  Assignee(s): Pharmacia & Upjohn Company
  The present invention relates to a novel method for improving the pharmacokinetics of tipranavir, comprising administering to a human in need of such treatment a combination of a therapeutically effective amount of tipranavir or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of ritonavir or a pharmaceutically acceptable salt thereof.
  
  Patent expiration dates:
  
  
  • October 29, 2019
    
    ✓ 
    Patent use: TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR.
  
  
  
  • April 29, 2020
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Compounds useful to treat retroviral infections
  Patent 6,169,181
  Issued: January 2, 2001
  Inventor(s): Romines; Karen Rene & Bundy; Gordon L. & Schwartz; Theresa M. & Tommasi; Ruben A. & Strohbach; Joseph W. & Turner; Steven Ronald & Thaisrivongs; Suvit & Aristoff; Paul Adrian & Johnson; Paul D. & Skulnick; Harvey Irving & Skaletzky; Louis L. & Anderson; David John & Morris; Joel
  Assignee(s): Pharmacia & Upjohn Company
  The present invention relates to compounds of formula I and II which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus. ##STR1## wherein R.sub.10 and R.sub.20 taken together are: ##STR2##
  
  Patent expiration dates:
  
  
  • May 6, 2014
    
    ✓ 
    Drug substance
  
  
  
  • November 6, 2014
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
  Patent 6,231,887
  Issued: May 15, 2001
  Inventor(s): Gao; Ping & Morozowich; Walter
  Assignee(s): Pharmacia & Upjohn Company
  The present invention provides a novel pharmaceutical composition based on the use of a particular amount of basic amine which comprises a pyranone compound as a pharmaceutically active agent, a basic amine in an amount of from about 0.1% to about 10% by weight of the total composition, one or more pharmaceutically acceptable solvents, and one or more pharmaceutically acceptable surfactants. In addition, the composition may further comprises one or more pharmaceutically acceptable oils. The composition is in a form of self-emulsifying formulation which provides high concentration and high oral bioavailability for lipophilic pyranone compounds.
  
  Patent expiration dates:
  
  
  • July 27, 2018
    
    ✓ 
    Drug product
  
  
  
  • January 27, 2019
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • December 22, 2010 - PEDIATRIC EXCLUSIVITY
  
  
  • June 23, 2011 - USE OF APTIVUS, CO-ADMINISTERED W/RITONAVIR, FOR COMBINATION ANTIRETROVIRAL TREATMENT OF HIV-1 INFECTED PED (AGE 2-18 YRS) PATIENTS WHO ARE TREATMENT-EXPERIENCED AND INFECTED W/HIV-1 STRAINS RESISTANT TO MORE THAN ONE PROTEASE INHIBITOR
  
  
  • December 23, 2011 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Aptivus Consumer Information (Drugs.com)
• Aptivus Consumer Information (Wolters Kluwer)
• Aptivus Solution Consumer Information (Wolters Kluwer)
• Aptivus Consumer Information (Cerner Multum)
• Aptivus Advanced Consumer Information (Micromedex)
• Aptivus AHFS DI Monographs (ASHP)
• Tipranavir Consumer Information (Wolters Kluwer)
• Tipranavir Solution Consumer Information (Wolters Kluwer)
• Tipranavir Consumer Information (Cerner Multum)
• Tipranavir Advanced Consumer Information (Micromedex)
• Tipranavir AHFS DI Monographs (ASHP)